[
  {
    "ts": null,
    "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
    "summary": "BENSALEM, Pa., March 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit...",
    "url": "https://finnhub.io/api/news?id=6856e5b771aad0800f787d5009e8e4d5ba5e0ca399d80c00e3e16e95e171b743",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741348869,
      "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
      "id": 133091328,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "BENSALEM, Pa., March 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit...",
      "url": "https://finnhub.io/api/news?id=6856e5b771aad0800f787d5009e8e4d5ba5e0ca399d80c00e3e16e95e171b743"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
    "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
    "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741340054,
      "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
      "id": 133090283,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
      "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK",
    "summary": "NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=3ac06e4ffe27f7ce51504f21680a8759671a894b5fff6d58e377b1dd0620a927",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741326853,
      "headline": "Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK",
      "id": 133085981,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=3ac06e4ffe27f7ce51504f21680a8759671a894b5fff6d58e377b1dd0620a927"
    }
  },
  {
    "ts": null,
    "headline": "ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum",
    "summary": "ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's potential. See more here.",
    "url": "https://finnhub.io/api/news?id=0535ad1c5c678edf8db8db422a6767f5b19851fc580783249a2f1b83c8b2fa0a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741312048,
      "headline": "ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum",
      "id": 133084947,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/580503981/image_580503981.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's potential. See more here.",
      "url": "https://finnhub.io/api/news?id=0535ad1c5c678edf8db8db422a6767f5b19851fc580783249a2f1b83c8b2fa0a"
    }
  }
]